Mealey's (June 7, 2022, 12:38 PM EDT) -- SAN DIEGO — A federal judge in California on June 6 granted final approval of a $12.75 million settlement and awarded $4.25 million in attorney fees to class counsel in a securities class action against a pharmaceutical company and certain of its senior executives on claims that they misrepresented adverse clinical trial results for the company’s metastatic breast cancer (MBC) treatment candidate in violation of federal securities laws....